Every event, every penny, and every pound helps towards making a difference to the lives of patients living with NMO.

NMO Charitable Funds
Walton Centre: 4911
John Radcliffe: 2131

More Information

Clinical Trials

Current Clinical trials in NMOSD

  • Phase 1b study of ABX-1431 in patients with NMOSD and related disorders (ABIDE Therapeutics). ABX-1431 is new, potential therapy for chronic central neuropathic pain. It is an oral medication that modulates the endocannabinoid neurotransmitter system.  Oxford and Liverpool are the two centres for this trial. Trial closed and results pending.
  • Phase 3 double blind trial to evaluate the safety and efficacy of eculizumab in relapsing NMO patients (PREVENT Study, Alexion Pharmaceuticals). Eculizumab is a terminal complement inhibitor. This is an international trial. Dr Jacob is the lead investigator in the UK and we have three patients enrolled in the study in the UK. Trial closed and results were strongly positive